These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34692895)

  • 1. Long-term Efficacy of Perampanel in a Child with Dravet Syndrome.
    Turón-Viñas E; Díaz-Gómez A; Coca E; Dougherty L; Ruiz C; Boronat S
    Child Neurol Open; 2021; 8():2329048X211050711. PubMed ID: 34692895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of intractable life-threatening seizures with perampanel in the first case of early myoclonic encephalopathy with a novel de novo SCN1A mutation.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Itai T; Miyatake S; Kato M; Matsumoto N; Kobayashi M
    Seizure; 2019 Oct; 71():20-23. PubMed ID: 31176277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of perampanel in young children with drug-resistant epilepsy.
    Chang FM; Fan PC; Weng WC; Chang CH; Lee WT
    Seizure; 2020 Feb; 75():82-86. PubMed ID: 31901668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Dravet Syndrome: Characterization of a Novel, More Severe SCN1A-Linked Epileptic Encephalopathy.
    Beck VC; Hull JM; Isom LL
    Epilepsy Curr; 2019; 19(4):266-268. PubMed ID: 31257984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perampanel Reduces Hyperthermia-Induced Seizures in Dravet Syndrome Mouse Model.
    Ho SY; Lin L; Chen IC; Tsai CW; Chang FC; Liou HH
    Front Pharmacol; 2021; 12():682767. PubMed ID: 34335252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
    Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
    J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of SCN1A-related dravet syndrome among children reported with seizures following vaccination: a population-based ten-year cohort study.
    Verbeek NE; van der Maas NA; Jansen FE; van Kempen MJ; Lindhout D; Brilstra EH
    PLoS One; 2013; 8(6):e65758. PubMed ID: 23762420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies.
    Kwan P; Mintzer S; Laurenza A; Patten A; Cartwright K
    Epilepsy Behav Case Rep; 2018; 9():1-5. PubMed ID: 29707476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium Channel Gene Mutations in Children with GEFS+ and Dravet Syndrome: A Cross Sectional Study.
    TONEKABONI SH; EBRAHIMI A; BAKHSHANDEH BALI MK; TAHERI OTAGHSARA SM; HOUSHMAND M; NASEHI MM; TAGHDIRI MM; MOGHADDASI M
    Iran J Child Neurol; 2013; 7(2):31-6. PubMed ID: 24665294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome.
    Yoshitomi S; Takahashi Y; Yamaguchi T; Imai K; Ishii A; Hirose S; Inoue Y
    Epilepsy Res; 2019 Aug; 154():34-38. PubMed ID: 31035242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dravet Syndrome: A Developmental and Epileptic Encephalopathy.
    Lopez-Santiago L; Isom LL
    Epilepsy Curr; 2019 Jan; 19(1):51-53. PubMed ID: 30838929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience.
    Steinhoff BJ
    Ther Adv Neurol Disord; 2015 May; 8(3):137-47. PubMed ID: 25941541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myoclonic Absence Seizures in Dravet Syndrome.
    Myers KA; Scheffer IE
    Pediatr Neurol; 2017 May; 70():67-69. PubMed ID: 28233668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of perampanel in a patient with epilepsia partialis continua.
    Argente-Escrig H; Gómez-Ibáñez A; Villanueva V
    Epilepsy Behav Case Rep; 2017; 8():105-107. PubMed ID: 29062692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dravet syndrome: new potential genetic modifiers, imaging abnormalities, and ictal findings.
    Gaily E; Anttonen AK; Valanne L; Liukkonen E; Träskelin AL; Polvi A; Lommi M; Muona M; Eriksson K; Lehesjoki AE
    Epilepsia; 2013 Sep; 54(9):1577-85. PubMed ID: 23808377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel.
    Garcia-Borreguero D; Cano I; Granizo JJ
    Sleep Med; 2017 Jun; 34():105-108. PubMed ID: 28522077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Low-dose perampanel improved cortical myoclonus and basophobia in a patient with Unverricht-Lundborg disease: a case report].
    Oi Y; Kobayashi K; Hitomi T; Matsumoto R; Ikeda A; Takahashi R
    Rinsho Shinkeigaku; 2018 Oct; 58(10):622-625. PubMed ID: 30270337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A
    Ye Y; Hu Z; Mai J; Chen L; Cao D; Liao J; Duan J
    Front Pediatr; 2022; 10():759889. PubMed ID: 35386260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of Dravet Syndrome with a newly defined mutation in the SCN1A gene.
    Tunçer GÖ; Teber S; Albayrak P; Kutluk MG; Deda G
    Turk Pediatri Ars; 2018 Dec; 53(4):259-262. PubMed ID: 30872930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remarkable improvement of primary orthostatic tremor using perampanel.
    Grobe-Einsler M; Kaut O
    Neurol Res Pract; 2020; 2():3. PubMed ID: 33324909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.